Market News / Story
AVBP Stock Crashes More Than 48% To All-Time Low After Lung Cancer Trial Setback – Retail Calls It ‘Way Undervalued’
Stocktwits ·
Stocktwits reports: Shares of ArriVent BioPharma (AVBP) crashed over 48% to a record low on Tuesday after the biotech company said its experimental lung-cancer treatment failed to meet the main goal of a Phase 3 trial. AVBP stock also clocked its biggest ever single-day slump. Firmonertinib Misses Main Goal The Phase 3 Furvent study tested Firmonertinib as a first-line treatment for patients with advanced non-small cell lung cancer with mutations, a difficult-to-treat form of the disease.…